JPRN-jRCT2031210069
Completed
Phase 1
A Phase 1 study to assess the safety, tolerability, and immunogenicity of VN-0200 after intramuscular injection in Japanese healthy adults and elderly subjects
Inoguchi Akihiro0 sites48 target enrollmentMay 7, 2021
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Prevention of respiratory syncytial virus
- Sponsor
- Inoguchi Akihiro
- Enrollment
- 48
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Japanese healthy subjects.
- •2\. Age \>\=20 and \<\=50 years upon providing informed consent at step1 or Age \>\=65 and \<\=80 years upon providing informed consent at step2\.
- •3\. Body mass index (BMI) \>\=18\.0 and \<30\.0 kg/m2 at screening.
Exclusion Criteria
- •1\. Subjects with a history of anaphylaxis or severe allergies due to food, medicine, insect bites, cosmetics, or vaccination
- •2\. Having alcohol or drug dependence etc.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
Safety and pharmacokinetics study in healthy Japanese volunteersJPRN-jRCT2051210087Owada Yasuko48
Completed
Not Applicable
A Phase I study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of HTX-011-19 (a long acting formulation of 5% bupivacaine and 0.15% meloxicam) and HTX-011-49 (a long acting formulation of 2.5% bupivacaine and 0.075% meloxicam) after subcutaneous administration in healthy subjects.post-operative painanalgesicsNL-OMON41936Heron Therapeutics, Inc.46
Completed
Phase 1
ART-001 Phase 1 studyHealthy volunteersJPRN-jRCT2080225277ARTham Therapeutics Inc.32
Completed
Phase 1
A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeated doses of ART-648/TAK-648 in healthy Japanese volunteersHealthy volunteersJPRN-UMIN000034454Dept of Clinical Pharmacology and Therapeutics, Oita University Faculty of Medicine44
Completed
Not Applicable
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of OMS1029 with single-dose intravenous and subcutaneous administration in healthy subjectsNL-OMON53550Omeros Corporation48